{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:01:49Z","timestamp":1772121709958,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vaccine.2022.02.029","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T15:52:11Z","timestamp":1644335531000},"page":"2068-2075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity"],"prefix":"10.1016","volume":"40","author":[{"given":"Sonia","family":"P\u00e9rez-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiby","family":"de la Caridad Rodr\u00edguez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando","family":"Ochoa-Azze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanet","family":"Climent-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Alberto Gonz\u00e1lez-Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Paredes-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Valenzuela-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rodr\u00edguez-Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocmira","family":"Perez-Nicado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"Gonz\u00e1lez-Mugica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisel","family":"Mart\u00ednez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"S\u00e1nchez-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tays","family":"Hern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"D\u00edaz-Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura","family":"Tamayo-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alis","family":"Mart\u00edn-Trujillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorman","family":"Rubino-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anamary","family":"Su\u00e1rez-Batista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Dubed-Echevarr\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Teresa P\u00e9rez-Guevara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayt\u00e9","family":"Amoroto-Roig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanet","family":"Chappi-Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gretchen","family":"Bergado-B\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franciscary","family":"Pi-Estopi\u00f1\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Wu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yury","family":"Vald\u00e9s-Balb\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Garc\u00eda-Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Verez-Bencomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.02.029_b0005","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Geneva: WHO; 2021. Available from: https:\/\/covid19.who.int."},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.029_b0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.vaccine.2022.02.029_b0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/pathogens9030231","article-title":"SARS-CoV-2 and coronavirus disease 2019: what we know so far","volume":"9","author":"Rabi","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2022.02.029_b0020","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Shi-Lee","year":"2020","journal-title":"Nat. Microbiol."},{"issue":"7821","key":"10.1016\/j.vaccine.2022.02.029_b0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","article-title":"A perspective on potential antibody-dependent enhancement of SARS-CoV-2","volume":"584","author":"Arvin","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.029_b0030","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2022.02.029_b0035","unstructured":"World Health Organization. Considerations for evaluation of COVID19 vaccines. Version 24. Geneva: WHO; 2020."},{"issue":"6504","key":"10.1016\/j.vaccine.2022.02.029_b0040","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.02.029_b0045","doi-asserted-by":"crossref","unstructured":"Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: an international vaccine-recipient survey. medRxiv. the Preprint Server for Health Sciences. 2021. Available from: https:\/\/www.doi.org\/10.1101\/2021.02.26.21252096.","DOI":"10.1101\/2021.02.26.21252096"},{"key":"10.1016\/j.vaccine.2022.02.029_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01880","article-title":"The 2020 pandemic: current SARS-CoV-2 vaccine development","volume":"11","author":"Alturki","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.029_b0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-020-0358-6","article-title":"COVID-19 vaccines: neutralizing antibodies and the alum advantage","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"7830","key":"10.1016\/j.vaccine.2022.02.029_b0060","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.02.029_b0065","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine adjuvants: from 1929 to 2015 and Beyond","volume":"3","author":"Di Pasquale","year":"2015","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2022.02.029_b0070","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1590\/S0100-879X2012007500067","article-title":"Human prophylactic vaccine adjuvants and their essential role in new vaccine formulations","volume":"45","author":"P\u00e9rez","year":"2012","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.vaccine.2022.02.029_b0075","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fimmu.2013.00407","article-title":"Adjuvants are key factor for the development of future vaccines: lessons from the Finlay adjuvant platform","volume":"4","author":"P\u00e9rez","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.02.029_b0080","unstructured":"Brighton Collaboration. Case definitions. Basel: BC; 2021. Available from: https:\/\/brightoncollaboration.us\/category\/pubs-tools\/case-definitions\/. Accessed (August 10, 2021)."},{"key":"10.1016\/j.vaccine.2022.02.029_b0085","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Washington: HHS; 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed (August 10, 2021)."},{"key":"10.1016\/j.vaccine.2022.02.029_b0090","series-title":"Causality Assessment of an Adverse Event Following Immunization (AEFI)","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.vaccine.2022.02.029_b0095","series-title":"Program ELISA for Windows Use\u0155s Manual. Version 2.0","author":"Plikaytis","year":"2005"},{"key":"10.1016\/j.vaccine.2022.02.029_b0100","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.029_b0105","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/jmv.25986","article-title":"Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples","volume":"92","author":"Manenti","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2022.02.029_b0110","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/v13030418","article-title":"Target product profile analysis of COVID-19 vaccines in phase III clinical trials and beyond: an early 2021 perspective","volume":"13","author":"Funk","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2022.02.029_b0115","unstructured":"Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 2020;396:467-78. Available from: https:\/\/www.org\/10.1016\/S0140-6736(20)31604-4."},{"issue":"19","key":"10.1016\/j.vaccine.2022.02.029_b0120","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1\u20132a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"NEJM"},{"issue":"20","key":"10.1016\/j.vaccine.2022.02.029_b0125","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","article-title":"A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine","volume":"39","author":"Chu","year":"2021","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.029_b0130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.02.029_b0135","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","author":"Keech","year":"2020","journal-title":"NEJM"},{"key":"10.1016\/j.vaccine.2022.02.029_b0140","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","article-title":"Mechanisms of action of adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.02.029_b0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.37757\/MR2018.V20.N3.6","article-title":"Effectiveness of a Serogroup B and C meningococcal vaccine developed in Cuba","volume":"20","author":"Ochoa-Azze","year":"2018","journal-title":"MEDICC Rev"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.029_b0150","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1080\/21645515.2018.1438028","article-title":"Cross protection induced by VA-MENGOC-BC\u00ae vaccine","volume":"14","author":"Ochoa-Azze","year":"2018","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2200161X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2200161X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:10:53Z","timestamp":1759403453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2200161X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":30,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0264410X2200161X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.029","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.10.04.21264522","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}